Devyser’s breakthrough NGS product for hereditary breast and ovarian cancer testing now approved for diagnostic use in the EU
Swedish genetic test developer Devyser’s product for hereditary breast and ovarian cancer (HBOC) is now CE labelled and approved for diagnostic use in the EU. The kit is based on Devyser's patented next-generation sequencing library prep technology and provides targeted sequencing of 12 genes with a recognized connection to the development of breast and ovarian cancers, for a total of 14 genes when combined with Devyser’s BRCA test.Swedish genetic test developer Devyser’s product for hereditary breast and ovarian cancer (HBOC) is now CE labelled and approved for diagnostic use in the EU.